Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Twist Bioscience: Valuation Is Weighing On The Stock
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future.
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Sung-Ji Nam - Scotiabank Operator Good day. Thank you for standing by.
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago.
All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy
Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Twist Bioscience: Path To Profitability Beginning To Take Shape
Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and royalties to XOMA for a small amount. Twist's margins continue to improve, and the company now appears to be on a path to cash flow breakeven over the next few years.
Twist Bioscience: A Post-Earnings Assessment
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for several years even as revenues rise. The company does have a solid balance sheet and north of $1.2 billion in net loss carry forwards.
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Founder Adam Laponis - CFO Patrick Finn - President and COO Conference Call Participants Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Luke Sergott - Barclays Matt Larew - William Blair Puneet Souda - Leerink Partners Tom Peterson - Baird Chad Wiatrowski - TD Cowen Thomas DeBourcy - Nephron Research Rachel Vatnsdal - JPMorgan Operator Welcome to Twist Bioscience's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.81 per share a year ago.
